Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
Longer Follow-Up BRUIN Data Continues to Support Pirtobrutinib in MCL
September 5th 2023In an interview with Targeted Oncology, Nirav Shah, MD, discussed long-term follow-up results from the phase 1/2 BRUIN study and how the approval of pirtobrutinib has changed the MCL treatment landscape.
Read More
Olaparib With High-Dose Chemo and ASCT Shows Potential in R/R Lymphomas
August 18th 2023In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the implications of findings from the phase 1 study assessing olaparib and high-dose chemotherapy in patients with relapsed/refractory lymphomas.
Read More
Time to Discontinuation on Darolutamide Longer in nmCRPC
August 10th 2023Alicia K. Morgans, MD, MPH, discusses real-world evidence the shows patients with non-metastatic castration resistant prostate cancer on darolutamide have a longer time till discontinuation when compared with enzalutamide and apalutamide.
Watch
Zilovertamab With Ibrutinib Provides Durable Responses in MCL and CLL
August 9th 2023In an interview with Targeted Oncology, Hun Ju Lee, MD, discussed the encouraging responses shown with the combination of zilovertamab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia, and highlighted other studies making headway in the field.
Read More
Assessing Available CAR T-Cell Agents for DLBCL
August 7th 2023Frederick Locke, MD, reviews the current landscape of approved CAR T-cell therapies for patients with large B-cell lymphoma and how off the shelf options like ALLO-501 and ALLO-501A can fill the gap for patients waiting for treatment.
Watch